Asthma is increasingly recognised as a heterogeneous disease, with several phenotypes defined by clinical and inflammatory characteristics. Common phenotypes include allergic (eosinophilic, IgE-mediated), non-allergic (often neutrophilic or paucigranulocytic), late-onset adult asthma, obesity-associated asthma, and asthma with persistent airflow limitation.14 Identifying phenotypes supports individualised treatment strategies, particularly in those with severe asthma, and better long-term outcomes.
Steps 2 and 3: Maintenance and reliever therapy (MART)
Comorbid conditions can complicate asthma management. Assess for and help address factors such as allergic rhinitis, which affects up to 80% of people with asthma,24 as well as gastro-oesophageal reflux disease (GORD), anxiety, depression, obstructive sleep apnoea and smoking.
2025 federal election: what policy changes will pharmacists see?
From prescribing rights to aged care roles, the 2025 federal election could usher in pharmacy-led healthcare reform.
How pharmacists should address rising B6 overuse
Too many people are taking way too much Vitamin B6. A senior pharmacist explains the risks of high doses, and how the TGA is responding.
More PBS listings announced to support women’s health care
Several women’s health medicines will be on the Pharmaceutical Benefits Scheme after new PBAC recommendations.
Gripe Water
Gripe water has been a mainstay in pharmacies for over 170 years. But should it be something for parents to gripe about?
Are nebulisers about to be smashed into obscurity?
Pharmacists should brace for yet another medicine shortage. However, this one might actually be beneficial for patients.
Opioid pharmacotherapy: delivery in community pharmacy
The pharmacist’s guide to the different regulations and protocols across Australia.
Opioid substitution has been recognised globally as an effective harm minimisation strategy for...
